74 related articles for article (PubMed ID: 1573283)
1. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities.
Ozes ON; Reiter Z; Klein S; Blatt LM; Taylor MW
J Interferon Res; 1992 Feb; 12(1):55-9. PubMed ID: 1573283
[TBL] [Abstract][Full Text] [Related]
2. Identification of alpha interferon-induced genes associated with antiviral activity in Daudi cells and characterization of IFIT3 as a novel antiviral gene.
Schmeisser H; Mejido J; Balinsky CA; Morrow AN; Clark CR; Zhao T; Zoon KC
J Virol; 2010 Oct; 84(20):10671-80. PubMed ID: 20686046
[TBL] [Abstract][Full Text] [Related]
3. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon.
Berger Rentsch M; Zimmer G
PLoS One; 2011; 6(10):e25858. PubMed ID: 21998709
[TBL] [Abstract][Full Text] [Related]
4. Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice.
Fleischmann CM; Stanton GJ; Fleischmann WR
Cancer Immunol Immunother; 1994 Sep; 39(3):148-54. PubMed ID: 7923244
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy.
D'Atri S; Fuggetta MP; Giganti G; Tentori L; Roselli M; Nunziata C; Pastore S; Bonmassar E; De Vecchis L
Cancer Immunol Immunother; 1988; 27(2):163-70. PubMed ID: 3416325
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of a human cell strain, KT, with high sensitivity to UV-killing and to cell proliferation inhibition by interferon.
Suzuki N; Inaba N; Sugano I; Umehara S; Murakami T; Takakubo Y
Jpn J Cancer Res; 1988 Nov; 79(11):1184-92. PubMed ID: 3147274
[TBL] [Abstract][Full Text] [Related]
7. Human natural interferon-alpha producing cells.
Fitzgerald-Bocarsly P
Pharmacol Ther; 1993 Oct; 60(1):39-62. PubMed ID: 8127923
[TBL] [Abstract][Full Text] [Related]
8. Beyond antiviral: Interferon induced by bacteria maintains tolerance in the gut.
Yang Y; Cadwell K
J Exp Med; 2024 Jan; 221(1):. PubMed ID: 38091026
[TBL] [Abstract][Full Text] [Related]
9. Strategies for the Production of Soluble Interferon-Alpha
Grabarz F; Lopes APY; Barbosa FF; Barazzone GC; Santos JC; Botosso VF; Jorge SAC; Nascimento ALTO; Astray RM; Gonçalves VM
Life (Basel); 2021 May; 11(6):. PubMed ID: 34063766
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity of porcine interferon omega 7 against foot-and-mouth disease virus in vitro.
Li SF; Zhao FR; Gong MJ; Shao JJ; Xie YL; Chang HY; Zhang YG
J Med Virol; 2019 Feb; 91(2):208-214. PubMed ID: 30039874
[TBL] [Abstract][Full Text] [Related]
11. Update on the Use of Consensus Interferon in Difficult-to-Treat Hepatitis C Patients: A Review of Selected Posters From Digestive Disease Week May 20-25, 2006 Los Angeles, Calif.With commentary by:Fred Poordad, MDCedars-Sinai Medical CenterLos Angeles, Calif.
Gastroenterol Hepatol (N Y); 2006 Aug; 2(8 Suppl 7):1-12. PubMed ID: 28400710
[No Abstract] [Full Text] [Related]
12. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
13. Auto-induction expression of human consensus interferon-alpha in Escherichia coli.
EL-Baky NA; Linjawi MH; Redwan EM
BMC Biotechnol; 2015 Mar; 15():14. PubMed ID: 25886839
[TBL] [Abstract][Full Text] [Related]
14. Consensus interferon plus ribavirin for hepatitis C genotype 3 patients previously treated with pegylated interferon plus ribavirin.
Abbas Z; Tayyab GN; Qureshi M; Memon MS; Subhan A; Shakir T; Jafri W; Hamid S
Hepat Mon; 2013; 13(12):e14146. PubMed ID: 24358041
[TBL] [Abstract][Full Text] [Related]
15. The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.
Hassanein T; Shiffman ML; Zein NN
Gastroenterol Hepatol (N Y); 2007 Jun; 3(6 Suppl 20):4-32. PubMed ID: 23329897
[No Abstract] [Full Text] [Related]
16. IFN-α subtypes: distinct biological activities in anti-viral therapy.
Gibbert K; Schlaak JF; Yang D; Dittmer U
Br J Pharmacol; 2013 Mar; 168(5):1048-58. PubMed ID: 23072338
[TBL] [Abstract][Full Text] [Related]
17. Novel plant-derived recombinant human interferons with broad spectrum antiviral activity.
Koehler JW; Dupuy LC; Garrison AR; Beitzel BF; Richards MJ; Ripoll DR; Wallqvist A; Teh SY; Vaewhongs AA; Vojdani FS; Padgett HS; Schmaljohn CS
Antiviral Res; 2011 Dec; 92(3):461-9. PubMed ID: 22020161
[TBL] [Abstract][Full Text] [Related]
18. Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin.
Moore CM; George M; Van Thiel DH
Dig Dis Sci; 2011 Oct; 56(10):3032-7. PubMed ID: 21879283
[TBL] [Abstract][Full Text] [Related]
19. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.
Yee HS; Currie SL; Tortorice K; Cozen M; Shen H; Chapman S; Cunningham F; Monto A
Dig Dis Sci; 2011 Aug; 56(8):2439-48. PubMed ID: 21633833
[TBL] [Abstract][Full Text] [Related]
20. U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.
Ho SB; Aqel B; Dieperink E; Liu S; Tetrick L; Falck-Ytter Y; DeComarmond C; Smith CI; McKee DP; Boyd W; Kulig CC; Bini EJ; Pedrosa MC
Dig Dis Sci; 2011 Mar; 56(3):880-8. PubMed ID: 21221804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
